PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,984,839 | +14.8% | 287,834 | +58.5% | 0.00% | 0.0% |
| Q2 2023 | $2,600,640 | +336334.7% | 181,609 | +67.7% | 0.00% | – |
| Q1 2023 | $773 | -36.2% | 108,284 | +0.3% | 0.00% | – |
| Q4 2022 | $1,211 | -99.9% | 107,927 | -8.2% | 0.00% | -100.0% |
| Q3 2022 | $1,303,000 | +33.5% | 117,579 | +1.8% | 0.00% | – |
| Q2 2022 | $976,000 | +18.6% | 115,543 | +87.6% | 0.00% | – |
| Q1 2022 | $823,000 | -30.5% | 61,581 | +2.3% | 0.00% | – |
| Q4 2021 | $1,184,000 | -47.0% | 60,218 | -13.5% | 0.00% | -100.0% |
| Q3 2021 | $2,234,000 | -29.9% | 69,595 | -26.0% | 0.00% | 0.0% |
| Q2 2021 | $3,185,000 | +28.6% | 94,085 | +42.6% | 0.00% | 0.0% |
| Q1 2021 | $2,477,000 | +18.3% | 65,956 | +4.7% | 0.00% | 0.0% |
| Q4 2020 | $2,093,000 | -7.5% | 63,006 | +2.2% | 0.00% | 0.0% |
| Q3 2020 | $2,262,000 | +37.3% | 61,671 | +23.2% | 0.00% | 0.0% |
| Q2 2020 | $1,647,000 | +79.6% | 50,038 | +41.0% | 0.00% | – |
| Q1 2020 | $917,000 | -16.6% | 35,492 | +0.4% | 0.00% | – |
| Q4 2019 | $1,100,000 | – | 35,345 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 4,901,358 | $41,368,000 | 8.59% |
| Frazier Life Sciences Management, L.P. | 5,827,415 | $49,183,000 | 4.64% |
| Abingworth LLP | 1,435,106 | $12,112,000 | 3.88% |
| Penn Mutual Asset Management | 86,940 | $734,000 | 0.99% |
| 683 Capital Management, LLC | 1,440,000 | $12,153,000 | 0.86% |
| Western Standard LLC | 109,055 | $920,000 | 0.70% |
| MPM BioImpact LLC | 193,326 | $1,632,000 | 0.45% |
| Newtyn Management, LLC | 255,767 | $2,159,000 | 0.41% |
| StepStone Group LP | 422,085 | $3,562,000 | 0.38% |
| Avidity Partners Management LP | 1,919,800 | $16,203,000 | 0.37% |